Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328102 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05328102 is a Phase 2 study that was terminated before completion, run by Xencor. The registered enrollment target is 3 participants.
The verdict
NCT05328102, a Phase 2 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Tafasitamab
- BIOLOGICAL Plamotamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328102
The ClinicalTrials.gov registry entry for NCT05328102 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT05328102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328102 about?
NCT05328102 is a clinical study titled "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)". The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
What is the current status of trial NCT05328102?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-04-15. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT05328102?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (BIOLOGICAL), Plamotamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05328102?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.